Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul-Sep;42(3):252-254.
doi: 10.1016/j.htct.2019.07.005. Epub 2019 Sep 11.

Current treatment preferences in acute myeloid leukemia: a survey in Brazil

Rodrigo Doyle Portugal  1 , Márcio Luiz Moore Nucci  2
Affiliations

Current treatment preferences in acute myeloid leukemia: a survey in Brazil

Rodrigo Doyle Portugal et al. Hematol Transfus Cell Ther. 2020 Jul-Sep.

Abstract

Introduction: Most adults with acute myeloid leukemia (AML) will eventually relapse from their disease. The combination of 7-day cytarabine and an anthracycline on days 1-3 (the so called "7 + 3" regimen) can be considered standard of care of younger patients with AML. However, the treatment of the elderly ineligible for intensive chemotherapy remains a challenge. Low-dose of subcutaneous cytarabine or hypomethylating agents (HMA) have been studied this group. There are no studies investigating physician practice variation in treating AML in Brazil.

Methods: We developed a survey with ten questions in order to explore the approach to AML in Brazil.

Results: The sample size comprised 100 hematologists. Most reported regular (63%) or occasional (29%) treatment of AML patients. Karyotype analysis and polymerase chain reaction were available in 88% and 71% of institutions, respectively. Next generation sequencing analysis was used in 7% of instituitions. Younger patients receive the "7 + 3" protocol with continuous infusion of cytarabine and anthracycline in 98% of cases. The preferred anthracycline is daunorubicin (64%), followed by idarubicin (34%). The most prescribed daunorubicin dose was 60 mg/m2 (56%). Consolidation after CR with high cytarabine doses (HIDAC) was indicated by 84% of hematologists and 70% use 3 g/m2 twice a day for 3 days. Elderly and unfit patients received HMA (47%) as the preferred treatment.

Conclusion: We showed that the most prevalent AML treatments were according to current guidelines. There is room to improve on the availability of diagnostic tools and the capacity to perform bone marrow transplantation.

Keywords: Acute myeloid leukemia; Brazil; Survey; Treatment.

PubMed Disclaimer

References

    1. Vasu S., Kohlschmidt J., Mrózek K., Eisfeld A.K., Nicolet D., Sterling L.J. Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission. Blood Adv. 2018;2(13):1645–1650. - PMC - PubMed
    1. Döhner H., Weisdorf D.J., Bloomfield C.D. Acute Myeloid Leukemia. N Engl J Med. 2015;373(12):1136–1152. - PubMed
    1. Burnett A., Milligan D., Prentice A.G., Goldstone A.H., McMullin M.F., Hills R.K. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer. 2007;109(6):1114–1124. - PubMed
    1. Thomas X., Arthur C., Delaunay J., Jones M., Berrak E., Kantarjian H.M. A post hoc sensitivity analysis of survival probabilities in a multinational phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2014;14(1):68–72. - PubMed
    1. Bittencourt R., Bortolheiro T.C., Chauffaille M.L., Fagundes E.M., Pagnano K.B., Rego E.M. Guidelines on the treatment of acute myeloid leukemia: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular: project guidelines: Associação Médica Brasileira. Rev Bras Hematol Hemoter. 2016;38(1):58–74. - PMC - PubMed